PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trialAndrea Necchi, Filippo de Braud, E. Togliardi et al.|Investigational New Drugs|2014Cited by 54
Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trialAndrea Necchi, Roberto Salvioni, Luigi Mariani et al.|Annals of Oncology|2017Cited by 46
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02Andrea Necchi, Francesco Montorsi, Alessandro Larcher et al.|Urologic Oncology Seminars and Original Investigations|2021Cited by 42
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinomaGiuseppe Rosiello, Umberto Capitanio, Alessandro Larcher et al.|Urologic Oncology Seminars and Original Investigations|2022Cited by 41
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysisAlberto Martini, Andrea Necchi, Daniele Raggi et al.|Cancer Treatment Reviews|2022Cited by 34